| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/13/2002 | CA2425396A1 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1213018A1 Preventive and therapeutic agents for eye diseases |
| 06/12/2002 | EP1213014A2 Process and system for controlled-release drug delivery |
| 06/12/2002 | EP1213013A2 Process for preparing solid compositions of water-soluble, hardly water-soluble or water-insoluble active agents |
| 06/12/2002 | EP1212446A2 Viral replicons and viruses dependent on inducing agents |
| 06/12/2002 | EP1212410A2 Dna encoding the human serine protease eos |
| 06/12/2002 | EP1212353A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf) |
| 06/12/2002 | EP1212349A1 Recombinant subunit vaccine |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212120A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| 06/12/2002 | EP1212100A2 Delivery system for antidandruff agent |
| 06/12/2002 | EP1212099A2 Amphiphilic prodrugs |
| 06/12/2002 | EP1212098A2 Enzyme inhibitors |
| 06/12/2002 | EP1212097A2 Enzyme inhibitors |
| 06/12/2002 | EP1212096A2 Drug conjugates and methods of designing the same |
| 06/12/2002 | EP1212095A2 Process to make a sustained release formulation |
| 06/12/2002 | EP1212094A2 Delivery of antimicrobial toxins |
| 06/12/2002 | EP1212093A2 Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications |
| 06/12/2002 | EP1212092A2 High viscosity liquid controlled delivery system and medical or surgical device |
| 06/12/2002 | EP1212091A2 Polyoxyalkylene copolymers containing pourable liquid vehicles |
| 06/12/2002 | EP1212085A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 06/12/2002 | EP1212084A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 06/12/2002 | EP1212079A1 Topical treatment of streptococcal infections |
| 06/12/2002 | EP1212077A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 06/12/2002 | EP1212074A1 Hybrid peptides modulate the immune response |
| 06/12/2002 | EP1212071A1 Stable carotene-xanthophyll beadlet compositions and methods of use |
| 06/12/2002 | EP1212069A2 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 06/12/2002 | EP1212061A1 Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol |
| 06/12/2002 | EP1212058A1 Topical treatment for prevention of ocular infections |
| 06/12/2002 | EP1212057A1 Extended duration light activated cancer therapy |
| 06/12/2002 | EP1212050A2 Formulations containing tetracyclinesfor treating or preventing mucositis |
| 06/12/2002 | EP1212046A2 Flushable disposable polymeric products |
| 06/12/2002 | EP1212045A1 A vaccine composition and method of using the same |
| 06/12/2002 | EP1212043A2 Composition to be administered through mucous membrane |
| 06/12/2002 | EP1212041A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 06/12/2002 | EP1212040A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 06/12/2002 | EP1212039A1 Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
| 06/12/2002 | EP1212034A1 Enzyme inhibitors |
| 06/12/2002 | EP1211942A1 Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution |
| 06/12/2002 | EP1082107A4 Controlled release lipoic acid |
| 06/12/2002 | EP1056474B1 Affinity markers for human serum albumin |
| 06/12/2002 | EP1039922B1 Improved interferon polymer conjugates |
| 06/12/2002 | EP0948357B1 Use of low molecular weight amino alcohols in ophthalmic compositions |
| 06/12/2002 | EP0941123B1 Nucleic acid complexed with cationic polymer useful for gene therapy |
| 06/12/2002 | EP0939655B1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 06/12/2002 | EP0935613B1 Acylated cyclodextrin derivatives |
| 06/12/2002 | EP0934080B1 1,3-bis-(n-lactamyl) propane and the pharmaceutical and cosmetic use thereof |
| 06/12/2002 | EP0914348B1 Polymers for delivering nitric oxide in vivo |
| 06/12/2002 | EP0855913B1 Iron dextran formulations |
| 06/12/2002 | EP0813407B1 Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate |
| 06/12/2002 | EP0788505B1 Poly-unsaturated carbohydrate derivatives, polymers thereof and their use |
| 06/12/2002 | EP0749325B1 Bispecific molecules having clinical utilities |
| 06/12/2002 | EP0697881B1 New cyclosporine-containing pharmaceutical compositions for oral administration |
| 06/12/2002 | EP0689427B1 Water dispersible therapeutic carotenoid compounds |
| 06/12/2002 | EP0678035B1 Vaccine preparations |
| 06/12/2002 | EP0574395B1 Cytokine immunoconjugates |
| 06/12/2002 | CN1353735A Silicone gel containing salicylic acid |
| 06/12/2002 | CN1353615A Compositions of A-beta peptide and processes for producing same |
| 06/12/2002 | CN1353613A Pharmaceutical compositions |
| 06/12/2002 | CN1353611A Balsam for treatment of surface burns and chafing rashes |
| 06/12/2002 | CN1353610A Medicinal composition for oral administration |
| 06/12/2002 | CN1353607A Improved pharmaceutical formulations |
| 06/12/2002 | CN1353581A Method and composition for masking mineral taste |
| 06/12/2002 | CN1086189C Ultra-fine microcrystalline cellulose compositions and process for their manufacture |
| 06/12/2002 | CN1086123C Low-viscosity cosmetic and pharmaceutical emulsions |
| 06/12/2002 | CA2364392A1 Compound |
| 06/11/2002 | US6403759 Polymers for delivering nitric oxide in vivo |
| 06/11/2002 | US6403758 Bioresorbable compositions for implantable prostheses |
| 06/11/2002 | US6403675 Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same |
| 06/11/2002 | US6403609 Topical-use lubricant that gels when administered to the eye |
| 06/11/2002 | US6403579 Treating cardiac and cardiovascular disorders and the illnesses associated therewith, hypertension, angina pectoris, cardiac insufficiency |
| 06/11/2002 | US6403565 Enhances dna repair and prevents consequences of mutagenic radiation even when administered after damage or exposure to radiation has already occurred; deoxyribonucleosides: deoxycytidine, deoxyadenosine, deoxyguanosine, and thymidine. |
| 06/11/2002 | US6403381 Using chelate compound |
| 06/11/2002 | US6403363 Method of preservation of vaccines with polybiguanide |
| 06/11/2002 | US6403123 Topical application of anthralin that results in minimal or no staining of skin or clothing; applying a wax formulation over the involved area |
| 06/11/2002 | US6403122 Bioavailability based on a lipolytic indifferent vehicle, an absorption promoter and active n-methylated cyclic undecapeptides or macrolide lactones; self assembly drug delivery system (sadds); cyclosporins |
| 06/11/2002 | US6403114 Having a reduced level of residual solvent(s); controlled-release microparticles having improved shelf-life |
| 06/11/2002 | US6403099 Conjugates formed from heat shock proteins and oligo-or polysaccharides |
| 06/11/2002 | US6403098 Buffer, sugar, phosphate, recombinant human serum albumin, polysorbate |
| 06/11/2002 | US6403096 Dimer, linked by a disulfide bridge; improves the uptake of therapeutic and diagnostic agents at a tumor site |
| 06/11/2002 | US6403092 Immune response modulator alpha-2 macroglobulin complex |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403077 Treatment regimes featuring an IL-10-containing chimeric polypeptide |
| 06/11/2002 | US6403057 Microcapsules, method of making and their use |
| 06/11/2002 | CA2124218C Cytotoxic drug therapy |
| 06/11/2002 | CA2101760C Composition made of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
| 06/11/2002 | CA2074050C Diclofenac sodium plaster |
| 06/11/2002 | CA2048638C Fibroblast growth factor (fgf)-based stabilized compositions and the use thereof |
| 06/09/2002 | WO2002067993A1 Drug-releasing system of biodegradable polymer type |
| 06/06/2002 | WO2002044396A1 Photochemical internalization for delivery of molecules into the cytosol |
| 06/06/2002 | WO2002044360A2 Modified arginine deiminase |
| 06/06/2002 | WO2002044336A2 Method of making a protein polymer and uses of the polymer |
| 06/06/2002 | WO2002044329A2 Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| 06/06/2002 | WO2002044324A2 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| 06/06/2002 | WO2002044271A2 Surfactant-containing cosmetic, dermatological and pharmaceutical agents |
| 06/06/2002 | WO2002044270A2 Use of comb copolymers based on acryloyldimethyltaurine acid in cosmetic, pharmaceutical and dermatological products |
| 06/06/2002 | WO2002044267A2 Cosmetic, pharmaceutical and dermatological products containing an electrolyte |
| 06/06/2002 | WO2002044231A1 Surfactant-free cosmetic, dermatological and pharmaceutical agents |
| 06/06/2002 | WO2002044230A2 Compositions containing copolymers based on acryloyldimethyl aminoethylsulfonic acid and synergistic additives |